FTC orders Mylan to divest two generics

09-09-2016

The US Federal Trade Commission (FTC) announced yesterday that it has approved a final order in Mylan’s $7.2 billion acquisition of Meda, a Swedish drug maker, deciding that the activity would be anticompetitive.


Mylan, Meda, FTC, anticompetitive, carisoprodol, felbamate

More on this story

Mylan, Edwards back NHK-Fintiv challenge
31-08-2021

LSIPR